Elevated glutamate levels in the brain's decision-making hub can contribute to early psychotic episode, which forecasts ...

Novel imaging research indicates that young adults with a higher genetic risk for depression showed less brain activity in several areas when ...

In a historic move for psychedelic medicine, Germany has granted the first-ever compassionate use approval for psilocybin in ...

Alterity Therapeutics Ltd. helped develop a new neuroimaging biomarker called the multiple system atrophy index (MSA-AI), which looks to be a more reliable biomarker for tracking disease progression ...

New Swinburne research has found that psychological stress may lead to higher blood pressure and therefore increase the risk ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Eisai (ESALF) and Eli Lilly (LLY) post new long-term data for thier Alzheimer's drugs Leqembi and Kisunla, respectively. Read more here.

There is only one way to fully understand neuroimaging techniques, such as electroencephalogram (EEG), which measures ...

In a revealing Genomic Press Interview published today in Brain Medicine, Dr. Camilo de la Fuente-Sandoval shares how ...

A new contract for transformational research to determine how menopause and modifiable lifestyle factors influence brain ...

Data are Consistent with Phase 2 Double-Blind Trial and Support Advancement of ATH434 in MSA – MELBOURNE, Australia and SAN FRANCISCO, (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ...

Neuroimaging markers such as MRI abnormalities, ischemia, and hydrocephalus predicted poor outcomes and mortality in CNS ...